MAP2K7 and primary cutaneous T-cell non-Hodgkin lymphoma: We and others have shown that NRAS mutations sensitize towards inhibition of MEK in cutaneous T-cell lymphoma, lung cancer and neuroblastoma cell lines [9, 12, 13, 15].